Source comparison
CJC-1295 No DAC Pulsatile GH Therapy: Protocol Comparison
CJC-1295 No DAC (Pulsatile) 100–200 mcg/dose 1–3× daily ~30 minutes Episodic activation, preserves receptor recycling Mimics endogenous GH pulse architecture, maintains insulin sensitivity Best for long-term protocols prioritizing metabolic health and receptor
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC (Pulsatile)
- 100–200 mcg/dose
- 1–3× daily
- ~30 minutes
- Episodic activation, preserves receptor recycling
- Mimics endogenous GH pulse architecture, maintains insulin sensitivity
- Best for long-term protocols prioritizing metabolic health and receptor sensitivity
- CJC-1295 With DAC (Sustained)
- 2 mg/week
- Once weekly
- 6–8 days
- Continuous activation, induces desensitization
- Dosing convenience, stable IGF-1 elevation
- Suitable for short-term studies where convenience outweighs physiological alignment
- Ipamorelin (GHS)
- 200–300 mcg/dose
- 2–3× daily
- ~2 hours
- Ghrelin receptor agonist, complementary to GHRH
- Synergistic with CJC no DAC via separate receptor pathway
- Ideal as combination therapy to amplify pulse magnitude without extending duration
- Modified GH (Exogenous)
- 2–4 IU/day
- Daily injection
- ~3 hours
- Direct GH receptor agonism
- Bypasses pituitary entirely, precise dose control
- Eliminates endogenous GH production, higher risk of insulin resistance and edema
- Combination protocols using CJC-1295 no DAC with growth hormone secretagogues like Ipamorelin or GHRP 2 exploit dual-pathway activation. GHRH analogs stimulate somatotroph cAMP signaling, while ghrelin receptor agonists activate PKC and intracellular calcium release. Two independent cascades that converge on GH secretion. Co-administration produces synergistic pulse amplification greater than either compound alone, without extending half-life or disrupting pulsatile rhythm.